. Author manuscript; available in PMC: 2021 May 1.

Published in final edited form as: Neurotoxicol Teratol. 2020 Apr 11;79:106883. doi: 10.1016/j.ntt.2020.106883

Table 3.

Monoamine neurotransmitters and metabolites (short-term exposure).

Tissue	Treatment	Sex	DA	DOPAC	HVA	5-HT	5-HIAA
Cortex	Control	female	20.36 ± 2.78	2.42 ± 0.25	3.85 ± 0.37	8.60 ± 0.3	5.79 ± 0.2^b
	Control	male	27.29 ± 2.78	2.66 ± 0.25	4.63 ± 0.37	8.21 ± 0.3	4.77 ± 0.2
	0.12% taurine	female	23.24 ± 2.78^a	2.36 ± 0.25	4.37 ± 0.37^a	8.61 ± 0.3	5.74 ± 0.2^b
	0.12% taurine	male	19.76 ± 2.78^a	2.01 ± 0.25	3.80 ± 0.37^a	8.18 ± 0.3	4.30 ± 0.2
Tissue	Treatment	Sex	DA	DOPAC	HVA	5-HT	5-HIAA
Hypothalamus	Control	female	6.04 ± 0.58	2.13 ± 0.13	3.20 ± 0.21	18.26 ± 0.42	11.06 ± 0.40^b
	Control	male	4.76 ± 0.58	1.84 ± 0.13	3.28 ± 0.21	17.98 ± 0.42	9.04 ± 0.40
	0.12% taurine	female	5.65 ± 0.58	1.94 ± 0.13	3.63 ± 0.21^c	19.33 ± 0.42^d	11.74 ± 0.40^b
	0.12% taurine	male	6.16 ± 0.58	2.0 ± 0.13	3.6 ± 0.21^c	18.79 ± 0.42^d	8.32 ± 0.40

Values are reported as ng/mg protein. Differences are indicated by bold text.

trend for sex * treatment interaction with higher levels in females and lower values in males compared to controls ,P < 0.1,

significantly higher in females P < 0.001,

trend for higher values in treated mice P < 0.1

significantly higher in taurine-treated mice.